Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $0.63, $0.14 better than the analyst estimate of $0.49. Revenue for the quarter came in at $288.9 million versus the consensus estimate of $274.38 million.

"We helped more tardive dyskinesia patients than ever before as our second quarter results reflect sustained growth for INGREZZA. While 8 out of 10 patients still remain undiagnosed, the underlying opportunity to improve the lives of patients with TD remains strong. Therefore, we continue to invest in healthcare provider and patient-focused awareness campaigns to help improve TD diagnosis and treatment rates," said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. "We remain committed to advancing our R&D pipeline and are making steady progress towards initiating 9 mid-to-late-stage clinical trials this year. With significant long-term commercial growth opportunities and a diverse and growing pipeline, we are well positioned to become a leading neuroscience-focused biopharmaceutical company."

GUIDANCE:

Full-Year 2021 Expense Guidance Reaffirmed

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.